A study of an investigational interatrial shunt for treating high-risk heart failure patients with reduced and preserved ejection fraction suggests the device has a high degree of safety and efficacy, ...

Please provide your email address to receive an email when new articles are posted on . Interatrial shunt implant lowered HF hospitalization risk for patients with HFrEF vs. placebo. However, patients ...

LOS GATOS, Calif., Oct. 27, 2024 /PRNewswire/ -- Adona Medical, a Shifamed portfolio company that aims to deliver advanced solutions for heart failure, announced today the successful first-in-human ...

10 patients enrolled with 100% implantation success Adona's adjustable interatrial shunt is designed so it can be modified post-implantation to provide a more adaptive and personalized lifetime ...

NEW ORLEANS, LA—A novel transcatheter intracardiac shunt device appears to provide sustained clinical benefit at 1 year in heart failure patients with preserved or only mildly reduced ejection ...

Shifamed portfolio company Adona Medical has raised $33.5m in a Series C financing round for supporting the next stage of product development and initiating clinical use of its interatrial shunt and ...

CAESAREA, Israel--(BUSINESS WIRE)--V-Wave Ltd, maker of an investigational interatrial shunt device for patients with advanced heart failure (HF), announced today the results of its first human ...

NEW ORLEANS, LA — For patients with heart failure with preserved ejection fraction, implantation of an interatrial shunt device appeared to be safe and was associated with clinical and hemodynamic ...

The Business Research Company's Interatrial Shunt Devices Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 Get 30% Off All Global Market Reports With Code ONLINE30 – Stay ...

LOS GATOS, Calif., June 17, 2025 /PRNewswire/ -- Adona Medical, a Shifamed portfolio company that is developing one of the world's first combined therapeutic ...